Class effects of SGLT2 inhibitors on cardiorenal outcomes

被引：0
|
作者：
Aaron Y. Kluger
Kristen M. Tecson
Andy Y. Lee
Edgar V. Lerma
Janani Rangaswami
Norman E. Lepor
Michael E. Cobble
Peter A. McCullough
机构：
[1] Baylor Heart and Vascular Institute,
[2] Baylor Scott & White Research Institute,undefined
[3] Texas A&M College of Medicine Health Science Center,undefined
[4] Baylor University Medical Center,undefined
[5] Baylor Heart and Vascular Hospital,undefined
[6] UIC/Advocate Christ Medical Center,undefined
[7] Einstein Medical Center,undefined
[8] Sidney Kimmel College of Thomas Jefferson University,undefined
[9] David Geffen School of Medicine at UCLA,undefined
[10] Cedars-Sinai Medical Center,undefined
[11] University of Utah School of Medicine,undefined
来源：
Cardiovascular Diabetology | / 18卷
关键词：
SGLT2 inhibitor; Empagliflozin; Canagliflozin; Dapagliflozin; CANVAS; EMPA–REG OUTCOME; DECLARE-TIMI 58; CREDENCE; Cardiovascular outcome trials; Heart failure hospitalization; Cardiovascular death; Albuminuria; Estimated glomerular filtration function; Chronic kidney disease; End-stage renal disease; Mortality;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Class effects of SGLT2 inhibitors on cardiorenal outcomes
    Kluger, Aaron Y.
    Tecson, Kristen M.
    Lee, Andy Y.
    Lerma, Edgar V.
    Rangaswami, Janani
    Lepor, Norman E.
    Cobble, Michael E.
    McCullough, Peter A.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2019, 18 (01)
  • [2] Cardiorenal effects of SGLT2 inhibitors: who might benefit?
    Klug, E.
    Rayner, B.
    Wasserfall, M.
    Kok, A.
    Mpe, M.
    Ruder, S.
    Mohamed, N. A.
    Webb, D.
    [J]. JOURNAL OF ENDOCRINOLOGY METABOLISM AND DIABETES OF SOUTH AFRICA, 2024, 29 (01) : 8 - 17
  • [3] SGLT2 inhibitors: glucosuria as an explanation for cardiorenal protective effects?
    Simon, Annika
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 (02) : 100 - 101
  • [4] Roles for SGLT2 Inhibitors in Cardiorenal Disease
    Green, Jennifer B.
    McCullough, Peter A.
    [J]. CARDIORENAL MEDICINE, 2022, 12 (03) : 81 - 93
  • [5] Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis
    Gronda, Edoardo
    Lopaschuk, Gary D.
    Arduini, Arduino
    Santoro, Antonio
    Benincasa, Giuditta
    Palazzuoli, Alberto
    Gabrielli, Domenico
    Napoli, Claudio
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2022, 100 (02) : 93 - 106
  • [6] Effects of SGLT2 inhibitors on cardiovascular outcomes
    Foote, Celine
    Perkovic, Vlado
    Neal, Bruce
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2012, 9 (02): : 117 - 123
  • [7] SGLT2 inhibitors: cardiorenal metabolic drugs for the ages
    Defronzo, Ralph A.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2024, 134 (05):
  • [8] An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
    Salvatore, Teresa
    Galiero, Raffaele
    Caturano, Alfredo
    Rinaldi, Luca
    Di Martino, Anna
    Albanese, Gaetana
    Di Salvo, Jessica
    Epifani, Raffaella
    Marfella, Raffaele
    Docimo, Giovanni
    Lettieri, Miriam
    Sardu, Celestino
    Sasso, Ferdinando Carlo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
  • [9] Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes
    Nazari, Somayeh
    Mirkhani, Hossein
    [J]. CURRENT DIABETES REVIEWS, 2023, 19 (08)
  • [10] Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes
    Theofilis, Panagiotis
    Sagris, Marios
    Oikonomou, Evangelos
    Antonopoulos, Alexios S.
    Siasos, Gerasimos
    Tsioufis, Kostas
    Tousoulis, Dimitris
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 188
12345